No Data
raily aesmed(02135.HK) has entered into a supply agreement with Suneva
Geelonghui, November 15th | Raily aesmed (02135.HK) announced that on January 24, 2024, the company entered into a supply agreement with Suneva, pursuant to which the company will acquire distribution rights and equity. The supply agreement will remain in effect until the fifteenth anniversary of January 24, 2024. After the initial term, upon mutual agreement of the company and Suneva, the supply agreement will be renewed for five years. Under the supply agreement, Suneva grants the company distribution rights, including the exclusive rights to use, sell, tender sales, register, import, export, and commercialize Bellafill in the Greater China region in the field of medical beauty.
raily aesmed (02135.HK) subsidiary failed to achieve profit guarantee, yesterday resold all equity to an independent third party.
Raily aesmed (02135.HK) announced that its indirectly wholly-owned subsidiary, Jumei Xinho, generated approximately 2.4 million RMB in net profit for the year ending March 31 this year, which is approximately 8.6 million RMB lower than the guaranteed net profit for the second relevant period. Therefore, it is believed that Jumei Xinho did not achieve the profit guarantee for the second relevant period. Raily aesmed also disclosed that its indirectly wholly-owned subsidiary, Shenzhen Ruiquan Management Consulting, entered into a sales agreement with two independent third parties, Peng Xiaonan and Ruan Zhiling, yesterday (6th). It is reported that Shenzhen Ruiquan Management Consulting agreed to sell all the equity of Jumei Xinho to the above-mentioned for 3.72 million RMB.
Raily Aesmed (02135) plans to sell 100% equity of Ju Mei Xinhe for 3.72 million yuan.
Raily Aesmed (02135) announced that due to JumeiXinhe's failure to achieve profit guarantee, on November 6, 2024, the...
Raily Aesmed (02135): Recognized an aggregate impairment loss on assets of approximately 47.1 million yuan.
Raily aesmed (02135) announced that after evaluating the impairment loss of the group assets, the board of directors of the company decided to...
Shenzhen is planning to relax market access for the medical beauty industry, encouraging social capital to enter the medical beauty sector.
Shenzhen has released the "Longhua District's Measures to Support the High-quality Development of the High-end Medical Beauty Industry (Draft for Soliciting Opinions)", mentioning the appropriate relaxation of market access for the medical beauty industry in Longhua District, encouraging social capital to enter the medical beauty industry. Establish a green channel for the approval of the medical beauty industry, simplify procedures such as enterprise registration and medical institution approval, and provide one-stop services for enterprises including industrial and commercial registration and administrative approval. At the same time, actively introduce leading medical beauty listed companies, service-oriented reputable medical beauty institutions, research and development medical beauty companies with mature products on the market, and medical beauty internet channel enterprises to land in Longhua, in accordance with relevant regulations.
RAILY AESMED: Interim Report 2024
No Data
No Data